{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T04:17:07Z","timestamp":1745468227728,"version":"3.37.3"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,5,24]],"date-time":"2022-05-24T00:00:00Z","timestamp":1653350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,5,24]],"date-time":"2022-05-24T00:00:00Z","timestamp":1653350400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urogynecol J"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1007\/s00192-022-05236-z","type":"journal-article","created":{"date-parts":[[2022,5,24]],"date-time":"2022-05-24T13:10:22Z","timestamp":1653397822000},"page":"729-736","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Urinary tract infection following intradetrusor onabotulinumtoxina injection for non-neurogenic urgency incontinence: single- vs. multi-dose prophylactic antibiotic treatment regimens"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2420-0838","authenticated-orcid":false,"given":"Tess","family":"Crouss","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youngwu","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erica","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vini","family":"Chopra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Fagan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lioudmila","family":"Lipetskaia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,5,24]]},"reference":[{"key":"5236_CR1","doi-asserted-by":"crossref","unstructured":"Gormley E, Lightner D, Burgio K. Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA\/SUFU Guideline.; 2019. http:\/\/www.auanet.org\/common\/pdf\/education\/clinical-guidance\/Overactive-Bladder.pdf.","DOI":"10.1097\/JU.0000000000000309"},{"issue":"1","key":"5236_CR2","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.eururo.2008.09.009","volume":"55","author":"A Apostolidis","year":"2009","unstructured":"Apostolidis A, Dasgupta P, Denys P. Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: A European consensus report. Eur Urol. 2009;55(1):100\u201320. https:\/\/doi.org\/10.1016\/j.eururo.2008.09.009.","journal-title":"Eur Urol"},{"issue":"1","key":"5236_CR3","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.juro.2008.03.028.Refractory","volume":"180","author":"L Brubaker","year":"2008","unstructured":"Brubaker L, Richter HE, Visco A. Refractory idiopathic urge urinary incontinence and botulinum A injection. J Urol. 2008;180(1):217\u201322. https:\/\/doi.org\/10.1016\/j.juro.2008.03.028.Refractory.","journal-title":"J Urol"},{"issue":"19","key":"5236_CR4","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1097\/01.ogx.0000427620.34769.ed","volume":"36","author":"AG Visco","year":"2012","unstructured":"Visco AG, Brubaker L, Richter HE. Anticholinergic therapy vs. onabotulinumtoxinA for urgency urinary incontinence. N Engl J Med. 2012;36(19):1803\u201313. https:\/\/doi.org\/10.1097\/01.ogx.0000427620.34769.ed.","journal-title":"N Engl J Med"},{"issue":"10","key":"5236_CR5","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1111\/ijcp.12443","volume":"68","author":"KD Sievert","year":"2014","unstructured":"Sievert KD, Chapple C, Herschorn S. OnabotulinumtoxinA 100U provides significant improvements in overactive bladder symptoms in patients with urinary incontinence regardless of the number of anticholinergic therapies used or reason for inadequate management of overactive bladder. Int J Clin Pract. 2014;68(10):1246\u201356. https:\/\/doi.org\/10.1111\/ijcp.12443.","journal-title":"Int J Clin Pract"},{"key":"5236_CR6","doi-asserted-by":"publisher","unstructured":"Lightner DJ, Wymer K, Sanchez J, Kavoussi L. Best Practice Statement on Urologic Procedures and Antimicrobial Prophylaxis. Am Urol Assoc Educ Res. 2019;1-65. https:\/\/doi.org\/10.1097\/JU.0000000000000509.","DOI":"10.1097\/JU.0000000000000509"},{"issue":"6","key":"5236_CR7","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1097\/JU.0000000000000789","volume":"203","author":"DJ Lightner","year":"2020","unstructured":"Lightner DJ, Wymer K, Sanchez J, Kavoussi L. Best Practice Statement on Urologic Procedures and Antimicrobial Prophylaxis. J Urol. 2020;203(6):351\u20136. https:\/\/doi.org\/10.1097\/JU.0000000000000789.","journal-title":"J Urol"},{"key":"5236_CR8","unstructured":"Allergan. Highlights of Prescribing Information. Allergan Pharmaceuticals. https:\/\/media.allergan.com\/actavis\/actavis\/media\/allergan-pdf-documents\/product-prescribing\/20190620-BOTOX-100-and-200-Units-v3-0USPI1145-v2-0MG1145.pdf. Published 2021."},{"issue":"13","key":"5236_CR9","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1001\/jama.2016.14617","volume":"316","author":"CL Amundsen","year":"2016","unstructured":"Amundsen CL, Richter HE, Menefee SA, et al. Onabotulinumtoxin a vs sacral neuromodulation on refractory urgency urinary incontinence in women: A randomized clinical trial. JAMA - J Am Med Assoc. 2016;316(13):1366\u201374. https:\/\/doi.org\/10.1001\/jama.2016.14617.","journal-title":"JAMA - J Am Med Assoc"},{"key":"5236_CR10","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1007\/s00192-018-3721-4","volume":"30","author":"J Houman","year":"2019","unstructured":"Houman J, Moradzadeh A, Patel D. What is the ideal antibiotic prophylaxis for intravesical botox injection? A comparison of two different regimens. Int Urogynecol J. 2019;30:701\u20134 http:\/\/ovidsp.ovid.com\/ovidweb.cgi?T=JS&PAGE=reference&D=emex&NEWS=N&AN=616357445.","journal-title":"Int Urogynecol J"},{"key":"5236_CR11","doi-asserted-by":"publisher","unstructured":"Eckhardt SE, Takashima Y, Handler SJ, Tenggardjaja C, Yazdany T. Antibiotic regimen and route of administration do not alter rates of urinary tract infection after intravesical botulinum toxin injection for overactive bladder. Int Urogynecol J. 2021. https:\/\/doi.org\/10.1007\/s00192-021-04691-4.","DOI":"10.1007\/s00192-021-04691-4"},{"issue":"9","key":"5236_CR12","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1007\/s00192-020-04230-7","volume":"31","author":"JA Bickhaus","year":"2020","unstructured":"Bickhaus JA, Vaughan M, Truong T, Li YJ, Siddiqui NY. A comparison of antibiotic prophylaxis regimens to decrease the risk of post-procedure urinary tract infection after onabotulinum toxin A injection. Int Urogynecol J. 2020;31(9):1907\u201312. https:\/\/doi.org\/10.1007\/s00192-020-04230-7.","journal-title":"Int Urogynecol J"},{"key":"5236_CR13","unstructured":"FDA. FDA In Brief: FDA warns that fluoroquinolone antibiotics can cause aortic aneurysm in certain patients | FDA. https:\/\/www.fda.gov\/news-events\/fda-brief\/fda-brief-fda-warns-fluoroquinolone-antibiotics-can-cause-aortic-aneurysm-certain-patients. Published 2018."},{"issue":"11","key":"5236_CR14","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1136\/bmj.n725","volume":"366","author":"TM Hooton","year":"2012","unstructured":"Hooton TM. Uncomplicated Urinary Tract Infection. N Engl J Med. 2012;366(11):1028\u201337. https:\/\/doi.org\/10.1136\/bmj.n725.","journal-title":"N Engl J Med"}],"container-title":["International Urogynecology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00192-022-05236-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00192-022-05236-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00192-022-05236-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T00:04:18Z","timestamp":1677110658000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00192-022-05236-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,24]]},"references-count":14,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["5236"],"URL":"https:\/\/doi.org\/10.1007\/s00192-022-05236-z","relation":{},"ISSN":["0937-3462","1433-3023"],"issn-type":[{"type":"print","value":"0937-3462"},{"type":"electronic","value":"1433-3023"}],"subject":[],"published":{"date-parts":[[2022,5,24]]},"assertion":[{"value":"1 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}